Takeda Q1 FY2026: Revenue Climbs 10% on Yen Weakness, Core Profit Flat; Full-Year Outlook Holds Steady
TAK sits 36% above its 52-week low of $12.99.
Summary
Takeda posted Q1 FY2026 revenue of JPY 1,219.9 billion, up 10.2% on a weak yen but down 0.5% at constant exchange rates. Core operating profit was flat in constant currency. Full-year guidance was maintained, implying a back-half weighted recovery.
Key Events · Earnings and Guidance · TAK
-
Q1 Revenue Up on FX, Flat Underlying
Revenue reached JPY 1,219.9 billion, a 10.2% increase in reported terms, but declined 0.5% at constant exchange rates (CER). Growth was driven by GI (ENTYVIO +15.4% reported) and Oncology (ADCETRIS +30.3% reported), offset by Neuroscience (VYVANSE -6.5% reported).
-
Core Operating Profit Flat at CER
Core Operating Profit was JPY 358.9 billion, up 11.5% reported but down 0.5% CER. Higher R&D expenses (+6.8% CER) and SG&A (+1.6% CER) offset gross margin improvement from favorable product mix.
-
Net Profit Drops on Higher Taxes, Restructuring
Net profit attributable to owners fell 8.9% to JPY 113.2 billion, pressured by a JPY 23.1 billion increase in income tax expenses (due to deferred tax asset reassessment) and a JPY 35.8 billion rise in restructuring costs.
-
Full-Year Guidance Unchanged
Management maintained FY2026 forecasts: Revenue JPY 4,640 billion, Operating Profit JPY 420 billion, Core EPS JPY 472. At CER, this implies a low-single-digit revenue decline, 5-8% Core Operating Profit decline, and mid-teens Core EPS decline.
Analysis · TAK · Life Sciences
Takeda's Q1 FY2026 results present a nuanced picture. Reported revenue surged 10.2% to JPY 1,219.9 billion, yet the entire gain stemmed from a weaker yen—on a constant currency basis, revenue edged down 0.5%. Core Operating Profit, which excludes one-time items, rose 11.5% in yen terms but was essentially flat (-0.5%) after adjusting for currency. The bottom line felt the weight of higher taxes and restructuring costs, with net profit falling 8.9%. Management left its full-year forecast unchanged, projecting a low-single-digit revenue decline and a mid-teens drop in Core EPS on a constant currency basis. Maintaining guidance despite a soft start in constant currency terms signals confidence in the second half, though the heavy reliance on a weak yen for reported growth and ongoing restructuring charges remain key watchpoints.
At the time of this filing, TAK was trading at $17.70 on NYSE in the Life Sciences sector, with a market capitalization of approximately $57.1B. The 52-week trading range was $12.99 to $18.90. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.